Back to resultsA STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE
Primary Purpose
Parkinson's Disease
Status
Unknown status
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
CJH1 (CLR4001)
Sponsored by
About this trial
This is an interventional treatment trial for Parkinson's Disease focused on measuring Novel Treatment Parkinson's disease
Eligibility Criteria
Inclusion Criteria:
- Patient's with Parkinson's disease
Exclusion Criteria:
- Contraindications to study medication
Sites / Locations
- Gateway Rural Health ResearchRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Treatment with CJH1
Arm Description
Outcomes
Primary Outcome Measures
Reduced signs and symptoms of Parkinson's disease
Reduced signs and symptoms of Parkinson's disease
Secondary Outcome Measures
Full Information
NCT ID
NCT01684475
First Posted
September 11, 2012
Last Updated
September 12, 2012
Sponsor
Alexandra Marine and General Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01684475
Brief Title
A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE
Official Title
A STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON'S DISEASE
Study Type
Interventional
2. Study Status
Record Verification Date
September 2012
Overall Recruitment Status
Unknown status
Study Start Date
September 2012 (undefined)
Primary Completion Date
September 2013 (undefined)
Study Completion Date
September 2013 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Alexandra Marine and General Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to assess the ability of CJH1 to increase the sensitivity of dopamine receptors and thereby reduce symptoms of Parkinson's Disease.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson's Disease
Keywords
Novel Treatment Parkinson's disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
N/A
Enrollment
21 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Treatment with CJH1
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
CJH1 (CLR4001)
Primary Outcome Measure Information:
Title
Reduced signs and symptoms of Parkinson's disease
Description
Reduced signs and symptoms of Parkinson's disease
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient's with Parkinson's disease
Exclusion Criteria:
Contraindications to study medication
Facility Information:
Facility Name
Gateway Rural Health Research
City
Goderich
State/Province
Ontario
ZIP/Postal Code
N7A 1W5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Craig Hudson, MD
Phone
519-524-8323
First Name & Middle Initial & Last Name & Degree
Craig J Hudson, MD
12. IPD Sharing Statement
Learn more about this trial
A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE
We'll reach out to this number within 24 hrs